August Bioservices

August Bioservices

US-based CDMO for end-to-end drug development

Overview

August Bioservices is a US-based CDMO offering end-to-end drug development and manufacturing from pre-clinical to commercial. It combines large-CDMO scale with a customer-focused hybrid model to serve startups and big pharma. It provides full development programs including research, development, testing, lab services, and sterile fill/finish under one integrated process, ensuring cGMP and FDA-quality standards. Its goal is to help clients bring safe, effective drugs to market efficiently through a seamless, integrated pathway.

About August Bioservices

Simplify's Rating
Why August Bioservices is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & Manufacturing

Healthcare

Company Size

51-200

Company Stage

Series B

Total Funding

$88.6M

Headquarters

Nashville, Tennessee

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • The $65 million Series B funds new filling capacity and automation.[4][6]
  • Clinical-to-commercial capabilities create expansion revenue as programs advance.[1][2][5]
  • Leadership credibility supports business development with biopharma sponsors.[9][1]

What critics are saying

  • Large CDMOs like Catalent and Thermo Fisher pressure pricing and win integrated programs.
  • Sterile injectable projects require heavy validation, making capacity additions slow to monetize.[4][6]
  • A contamination event or FDA enforcement action would severely disrupt single-source customer supply.

What makes August Bioservices unique

  • August focuses on sterile injectables, not broad-modality CDMO work.[1][2][7]
  • Its integrated lab-to-commercial platform reduces handoffs across development and manufacturing.[2][5]
  • It offers fully isolated filling lines for vials, syringes, and IV bags.[2][3]

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$88.6M

Above

Industry Average

Funded Over

2 Rounds

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Above Average

Industry standards

$35M
$45M
Linktree
$65M
Substack
$65M
August Bioservices
$100M
ClickUp

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Profit Sharing

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Student Loan Assistance

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Pet Insurance

Bereavement Leave

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Wellness Program

Mental Health Support

Gym Membership

Commuter Benefits

Meal Benefits

Phone/Internet Stipend

Home Office Stipend

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

1%
The Healthcare Technology Report
Mar 18th, 2026
Jenn Adams named Healthcare Technology CEO of the Year.

Jenn Adams named Healthcare Technology CEO of the Year. Published. March 18, 2026 At this year's NYC Awards Night, The Healthcare Technology Repo had the privilege of recognizing several exceptional leaders advancing innovation across healthcare technology. Congratulations to Jenn Adams, CEO of August Bioservices, on being named Healthcare Technology CEO of the Year. Jenn has led August Bioservices since its founding in 2020, building a contract development and manufacturing organization (CDMO) dedicated to sterile injectable therapies. Headquartered in Nashville, the company provides development and manufacturing services that help drug developers advance innovative therapies from early development through commercialization. Accepting the award, Jenn shared: "When we started our company five and a half years ago, we had a really clear goal and we set out to build a CDMO focused on sterile injectables that could truly serve as a partner to our clients, providing deep technical expertise and a state-of-the-art facility and equipment - all designed to help advance innovative therapies through development and commercialization. Our aspiration is to show up so fully for our clients that they cannot tell the difference anymore. It's indistinguishable to them who is on their team and who is on our team because we're working shoulder to shoulder to make sure the drug is advanced. And then we're bridging the innovation and bringing it to patients who need that innovation in the form of therapies." Please join The Healthcare Technology Repo in congratulating Jenn Adams on this well-deserved recognition. Picture: Jenn Adams speaks at NYC Awards Night

Teknovation.biz
Dec 13th, 2024
Tennessee Emerges As A Leading State For Bioscience R&D

A new report from the Biotechnology Innovation Organization (BIO) and TEConomy Partners LLC finds Tennessee has emerged as a leading state for bioscience research and development, with bioscience RD accounting... The post Tennessee emerges as a leading state for bioscience RD appeared first on Teknovation.biz.

Teknovation.biz
Jun 30th, 2024
News & Notes | Ut Research Foundation Welcomes Four Interns

Like this story? Please share!News & Notes | UT Research Foundation welcomes four interns ETSU's Innovation Lab Director Dr. Audrey Depelteau served as a judge at last week's 2024 SelectUSA Investment Summit.From Knoxville:To promote the commercialization of University of Tennessee (UT) innovations and to help train the next generation of commercialization professionals, the UT Research Foundation (UTRF) recently welcomed three new interns and one returning intern across its Knoxville and Memphis offices.In Knoxville, Andrea Gutierrez-Cortez and Lauren Williams , rising second-year law students at UT, Knoxville (UTK), joined the team as Commercialization Analysts. Jacob Hale is returning for his second year with UTRF as a Senior Commercialization Analyst. Hale is a rising third-year law student, while Gutierrez-Cortez completed her bachelor’s degree in human biology at the University of California, San Diego, and Williams majored in biomedical engineering at UTK.and , rising second-year law students at UT, Knoxville (UTK), joined the team as Commercialization Analysts. is returning for his second year with UTRF as a Senior Commercialization Analyst. Hale is a rising third-year law student, while Gutierrez-Cortez completed her bachelor’s degree in human biology at the University of California, San Diego, and Williams majored in biomedical engineering at UTK

Teknovation.biz
Oct 22nd, 2023
News & Notes | Expansion Bucks For August Bioservices

Like this story? Please share!. .

Teknovation.biz
Jan 23rd, 2023
Launch Tennessee Provides Ssbci Update, Q4 Tn Deal Flow

Like this story? Please share!. .

Recently Posted Jobs

Sign up to get curated job recommendations

August Bioservices is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →